# Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food

> **NCT02562859** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 500 mg GLPG1837 as oral suspension
- **DRUG:** 500 mg GLPG1837 as oral tablet

## Key facts

- **NCT ID:** NCT02562859
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02562859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02562859, "Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02562859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*